Pulmonx Corporation (Nasdaq: LUNG) ('Pulmonx” or the 'Company'), a global leader in minimally invasive treatments for lung ...
Pulmonx is positioned at the bottom for Revenue Growth, with a negative growth rate. It is also at the bottom for Gross ...
TipRanks on MSN
Pulmonx Corporation Reports Q3 2025 Financial Results
Pulmonx Corporation ( ($LUNG) ) has released its Q3 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its ...
Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsGlendon French - CEO, President & DirectorDerrick ...
AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback